Clinical trials: Malignant Melanomas
Advanced Solid Tumor, Uveal Melanoma, Metastatic
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
The Phase I trial is evaluating safety, tolerability, pharmacokinetics and preliminary efficacy of MBS8(1V270) in subjects with advanced solid tumours.
- Conditions
- Advanced Solid Tumor, Uveal Melanoma, Metastatic, Cutaneous Melanoma
- Trial name
- NCT04855435
- Testing
- MBS8(1V270), MBS8(1V270) and pembrolizumab combination
- Where
- 5 sites in Denmark, Spain
- Volunteers
- 106 people
- Sponsor
- MonTa Biosciences ApS
Melanoma, Lung Cancer
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) in Patients with Advanced Solid Tumors
- Conditions
- Melanoma, Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT03050047
- Testing
- BCD-100
- Where
- 4 sites in Russia
- Volunteers
- 15 people
- Sponsor
- Biocad
Metastatic Melanoma
Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma
This is an open-label, single dose study for patients 18 years of age or older with confirmed metastatic melanoma. Up to 12 patients will be enrolled and all will receive an injection of approximately 4.0 to 6.0 mCi (148-222 MBq)…
- Trial name
- NCT00747825
- Testing
- 131-I-MIP-1145
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors
Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrades arginine. ADI has been formulated with polyethylene glycol, and has been used to treat patients that have cancers…
- Trial name
- NCT01665183
- Testing
- ADI-PEG 20
- Where
- 2 sites in United States, Taiwan
- Volunteers
- 8 people
- Sponsor
- Polaris Group
Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome
A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome
Before switching to the post-marketing study: To evaluate the efficacy and safety of KRN23 after its 144-week once every 4 weeks (Q4W) repeated SC administration to Japanese and Korean patients with TIO or ENS by a multicenter…
- Trial name
- NCT02722798
- Testing
- KRN23
- Where
- 3 sites in Japan, South Korea
- Volunteers
- 14 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Melanoma
M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma
Previous studies suggests that M-Vax, a melanoma vaccine prepared from patients own cancer cells, can stimulated patients' immune system to react against their cancer.
- Trial name
- NCT00477906
- Testing
- M-Vax- autologous, hapten-modified melanoma vaccine
- Volunteers
- 387 people
- Sponsor
- AVAX Technologies
Solid Tumor, Colorectal Cancer
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or…
- Conditions
- Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer
- Trial name
- NCT03872947
- Testing
- TRK-950, Irinotecan, Leucovorin
- Where
- 14 sites in United States, France
- Volunteers
- 138 people
- Sponsor
- Toray Industries, Inc
Melanoma
A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma
This is a prospective, open-label, non-randomized, multicenter study in adults, aged eighteen (18) or older, with newly-diagnosed or recurrent unresectable Stage III or Stage IV melanoma.
- Trial name
- NCT00272415
- Testing
- INO-1001, temozolomide
- Volunteers
- 39 people
- Sponsor
- Genentech, Inc.
Advanced Melanoma, Metastatic Melanoma
PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
The purpose of this study is to evaluate pharmacodynamic changes of Nivolumab and Nivolumab in combination with Ipilimumab treatment on the biomarkers measured in the peripheral blood and tumor tissues of subjects with advanced…
- Trial name
- PD-1 (NCT01621490)
- Testing
- Nivolumab, Ipilimumab
- Where
- 14 sites in United States, Netherlands and 1 more
- Volunteers
- 170 people
- Sponsor
- Bristol-Myers Squibb
Malignant Melanoma
A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide
The purpose of the study is to determine Efficacy, Safety and Tolerability of MDX-010 (BMS-734016) administered with or without Prophylactic Oral Budesonide.
- Trial name
- NCT00135408
- Testing
- Ipilimumab+ Budesonide
- Where
- 10 sites in United States, Canada and 4 more
- Volunteers
- 115 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumors
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
- Trial name
- NCT06953089
- Testing
- DB-1311/BNT324, BNT327, DB-1305/BNT325
- Where
- 37 sites in United States, Australia and 2 more
- Volunteers
- 750 people
- Sponsor
- DualityBio Inc.
Solid Tumors, Cancer
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
This is a Phase 2 study to evaluate the efficacy and safety of cabozantinib (XL184) in subjects with selected advanced tumor types.
- Trial name
- NCT00940225
- Testing
- Cabozantinib
- Where
- 47 sites in United States, Belgium and 3 more
- Volunteers
- 730 people
- Sponsor
- Exelixis
Soft Tissue Sarcoma, Melanoma
TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors
This project is a clinical trial on the efficacy and safety of TQB2916 injection combined with chemotherapy or penpulimab injection in solid tumors. This project is divided into two cohorts.
- Trial name
- NCT06500091
- Testing
- TQB2916 injection + doxorubicin hydrochloride for injection, TQB2916 injection+penpulimab injection
- Where
- 11 sites in China
- Volunteers
- 54 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Choroidal Melanoma, Indeterminate Lesions
Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects
To assess subject-centric evidence of QoL outcomes in a subset of subjects enrolled in the global Phase 3 AU-011-301 clinical trial.
- Conditions
- Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
- Trial name
- NCT07421739
- Testing
- Non-interventional, digital, patient-reported, study
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- Aura Biosciences
Metastatic Melanoma
Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma
A phase 2, open-label randomized, multicenter trial to compare CC-486 in combination with Abraxane administered weekly with respect to overall survival, objective tumor response rate and Progression-Free Survival (PFS) in…
- Trial name
- NCT01933061
- Testing
- Abraxane
- Sponsor
- Celgene Corporation
Stage IV Melanoma, Stage III Melanoma
Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma
The purpose of this study is to determine the safety, tolerability and recommended phase 2 dose of a new drug, known as IMP321, in combination with pembrolizumab when given to patients with unresectable or metastatic melanoma.
- Trial name
- TACTI-mel (NCT02676869)
- Testing
- IMP321 (eftilagimod alpha), Pembrolizumab
- Where
- 7 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Immutep Australia Pty. Ltd.
Gastric Cancer, Renal Cell Carcinoma
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study.
- Conditions
- Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma
- Trial name
- NCT05238883
- Testing
- HFB200301, Tislelizumab
- Where
- 10 sites in United States, Spain
- Volunteers
- 72 people
- Sponsor
- HiFiBiO Therapeutics
NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
This is a multicenter, open-label, randomized (1:1) trial designed to evaluate whether ctDNA-guided interruption of immune-checkpoint inhibitor (ICI) therapy provides comparable survival to standard of care (SoC) continuous ICI…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC
- Trial name
- SIGNAL-IO 301 (NCT07689812)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 920 people
- Sponsor
- Natera, Inc.
Melanoma
Evaluation of Pigmented Skin Lesions With MelaFind(R) System
The purpose of this clinical trial is to demonstrate that MelaFind®, a new instrument that uses machine vision for non-invasive early detection of cutaneous pigmented malignant melanoma, is safe and effective.
- Trial name
- NCT00434057
- Testing
- MelaFind(R)
- Where
- 2 sites in United States
- Volunteers
- 1,383 people, healthy volunteers welcome
- Sponsor
- MELA Sciences, Inc.
Ovarian Neoplasms, Non-Small-Cell Lung Carcinoma
A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.
A phase I study of LTT462 in patients with advanced solid tumors that harbor MAPK pathway alterations.
- Conditions
- Ovarian Neoplasms, Non-Small-Cell Lung Carcinoma, Melanoma, Other Solid Tumors
- Trial name
- NCT02711345
- Testing
- LTT462
- Where
- 7 sites in United States, Germany and 4 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.